Human lymphocytes were treated with human alpha (IFN-oa), beta (IFN-,), or recombinant gamma (IFN--y) interferons separately or in combination to determine their ability to enhance natural killing against mouse L cell targets. Our results showed that recombinant IFN--y was approximately 50 times more active per unit of antiviral activity than either IFN-a or IFN-P. Moreover, the levels of natural killing by lymphocytes treated with combinations of IFN-a and IFN-, were additive, whereas combinations of recombinant IFN--y and IFN-a or recombinant IFN--y and IFN-p were synergistic. The development of natural killing in lymphocytes treated with recombinant IFN--y did not occur more rapidly but reached higher levels (62%) than that observed with lymphocytes treated with IFN-a or IFN-j (15%). The results suggest the importance of IFN--y and mixtures of IFN--y with IFN-a or IFN-1 in the enhancement of natural killing activity against virus infections and neoplasia.
Human lymphocytes were treated with human alpha (IFN-oa), beta (IFN-,), or recombinant gamma (IFN--y) interferons separately or in combination to determine their ability to enhance natural killing against mouse L cell targets. Our results showed that recombinant IFN--y was approximately 50 times more active per unit of antiviral activity than either IFN-a or IFN-P. Moreover, the levels of natural killing by lymphocytes treated with combinations of IFN-a and IFN-, were additive, whereas combinations of recombinant IFN--y and IFN-a or recombinant IFN--y and IFN-p were synergistic. The development of natural killing in lymphocytes treated with recombinant IFN--y did not occur more rapidly but reached higher levels (62%) than that observed with lymphocytes treated with IFN-a or IFN-j (15%). The results suggest the importance of IFN--y and mixtures of IFN--y with IFN-a or IFN-1 in the enhancement of natural killing activity against virus infections and neoplasia.
Interferon gamma (IFN-y) has been shown to enhance natural killing at least 50-fold greater than IFN alpha (IFN-a) or IFN beta (IFN-P) (16) . Furthermore, combinations of IFN-y with IFN-a or IFN-P have been shown to potentiate natural killing activity five-to sevenfold (16) . However, in these studies, partially purified preparations of IFN--y were used that may have contained other types of biological activities that contribute to cytotoxicity (8, 10) . Therefore, we determined whether preparations of recombinant IFN-y potentiated natural killing activity to the same extent as partially purified natural IFN-y. In the present study, recombinant IFN--y also enhanced natural killing by lymphocytes approximately 50-fold over that observed with IFN-a or IFN-,B. Moreover, the results show that IFN-y is responsible for the potentiation of natural killing activity observed in IFN-,y preparations when they are tested in combination with IFN-a or IFN-P.
MATERUILS AND METHODS IFN assay. Human IFN was quantitated in human amnion WISH cells by using a previously described cytopathic effect inhibition microassay (1 (11) . Recombinant human IFN-y (1.7 x 104 U/mg of protein) was kindly provided by W. Fiers, Laboratorium Voor Moleculaire Biologie, Gent, Belgium (4). The methods of production and use of the specific antisera used in these studies have been previously described (11, 12 (Fig. 1) . The data show that natural killing by lymphocytes treated with recombinant IFN-y was much more enhanced at lower concentrations of IFN than lymphocytes treated with a Lymphocytes were cultured with the various IFNs for 18 h at 37°C. After washing out the IFN, the cells were cultured with L cells for 16 h at a ratio of 10 lymphocytes to 1 target cell, and the percent specific 5"Cr release was determined.
b Calculated from the standard curve constructed from the data in Fig. 1 . 
DISCUSSION
Various concentrations of all three types of IFN alone and in combination were compared for their relative abilities to enhance natural killing activity of human peripheral lymphocytes against mouse L cell targets. Our results show that natural killing by lymphocytes treated with IFN--y reached higher levels than that observed when lymphocytes were treated with similar levels of IFN-a or IFN-1 (Fig. 1) . The data show that IFN-y is approximately 50 times more effective and acts as rapidly as IFN-a or -1 in the enhancement of natural killing. Moreover, combinations of IFN--y with IFN-a or -enhanced natural killing an additional fivefold above the expected additive effect. These results extend and confirm our previous studies showing that crude IFN--y enhanced natural killing activity much more than IFN-a or IFN-1 and that combinations of crude IFN--y and IFN-a or -1 potentiated the natural killing activity by lymphocytes (15) . This potentiation could be especially important when low levels of IFN are present.
A crucial question regarding our earlier studies was whether IFN-y itself was responsible for part of the potentiation in the partially purified preparations. In this regard, the data presented here regarding recombinant human IFN--y indicate that the observed potentiation of natural killing activity was due to the IFN--y. More recently, we produced antibodies in rabbits to a synthetic peptide encoded by the 5' end of human IFN--y cDNA that neutralized the antiviral and natural killer activity of natural and recombinant IFN-y (9a). The fact that this specific antibody completely neutralized the potentiation ability of crude and recombinant preparations of IFN--y is further evidence that IFN-y is responsible for the potentiation (data not shown).
All three types of IFN derived from leukocytes or fibroblasts have been previously shown to enhance natural killing after in vivo and in vitro administration (9, 13, 14, 16) . In our studies, potentiated levels of natural killing by lymphocytes were only observed when either IFN-a or -1 was combined with IFN-,y. Thus, IFN-y and mixtures of IFN--y with IFN-a or -13 may be important in the natural killing activity of this population of cells during neoplasia and virus infections, especially early on, when low levels of endogenous IFN are thought to be present.
